Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing.

ABSTRACT: The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient's leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of cell populations that might negatively affect production of chimeric antigen receptor (CAR) T cells, such as myeloid cells. In this work, the effect of monocytes (CD14) on the level of activation, growth, and transduction efficiency was monitored across well plate and culture bag platforms using healthy donor leukapheresis. Removal of monocytes from leukapheresis improved the level of activation 2-fold, achieving the same level of activation as when initiating the process with a purified T cell starting material. Two activation reagents were test

SUBMITTER: Noaks E 

PROVIDER: S-EPMC7917474 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature